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Abstract
Fetal growth restriction (FGR) is the most common pregnancy complication in developed countries. Pregnancies
affected by FGR, frequently concur with complications and high risk of neonatal morbidity and mortality. To date, no
approved treatment is available for pregnant women affected with FGR. The objective of this study was to investigate
the contribution of galectin-3 (gal-3), a β-galactoside binding protein involved in pregnancy, placental function and
fetal growth. We demonstrated that lack of gal-3 during mouse pregnancy leads to placental dysfunction and drives
FGR in the absence of a maternal preeclampsia syndrome. Analysis of gal-3 deficient dams revealed placental
inflammation and malperfusion, as well as uterine natural killer cell infiltration with aberrant activation. Our results also
show that FGR is associated with a failure to increase maternal circulating gal-3 levels during the second and third
trimester in human pregnancies. Placentas from human pregnancies affected by FGR displayed lower gal-3 expression,
which correlated with placental dysfunction. These data highlight the importance of gal-3 in the promotion of proper
placental function, as its absence leads to placental disease and subsequent FGR.
Introduction
During the establishment of a mammalian pregnancy,
the placenta plays a critical role in controlling fetal-
maternal resource allocation and mediating fetal pro-
gramming of future disease. Placental function depends
on a healthy decidual environment, and inadequate
endometrial receptivity or inappropriate implantation
increase the incidence of anomalous placentation. Defects
in placentation often result in fetal growth restriction
(FGR), one of the most complex pregnancy complications
without currently available treatment aside delivery, most
often preterm1. Affecting up to 8% of pregnancies
worldwide, FGR is also associated with significant peri-
natal complications, such as increased risk of stillbirth,
neonatal long-term morbidity, obesity, type 2 diabetes,
and coronary disease later in life1–4. When not attribu-
table to structural or genetic defects of the fetus, FGR is
primarily caused by placental insufficiency5,6, but the
biological processes that promote placental insufficiency
and the subsequent progression to FGR are currently
poorly understood. To date, no treatment options are
available1.
Galectins, a family of soluble glycan-binding proteins
are increasingly recognized as powerful modulators of
pregnancy-associated processes including proper pla-
cental development. Among the galectin family members,
the chimera-type galectin-3 (gal-3, encoded by the Lgals3
gene) is highly expressed at the fetal-maternal interface7–
10. Gal-3 knock-down in mouse endometrium results in
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substantially less implanted embryos11, and dysregulation
of gal-3 is associated with several obstetrical complica-
tions resulting from placental dysfunction. These include
preeclampsia (PE), hemolysis elevated liver enzymes and
low platelets (HELLP) syndrome, small-for-gestational
age, and gestational trophoblastic disease12–16. At present,
the impact of dysregulated gal-3 expression in placental
development and pregnancy outcome has not been
addressed.
In this study, we found that gal-3 loss of function during
gestation altered the decidual compartment favoring a
pro-inflammatory milieu, which was accompanied by a
decrease in progesterone (P4) in the maternal circulation.
In the placental compartment, lack of gal-3 compromised
placental vascularization and perfusion resulting in pla-
cental insufficiency and the subsequent development of
asymmetric FGR in mice. Using the prospective birth
cohort PRINCE (Prenatal Determinants of Children’s
Health), we showed that development of FGR is accom-
panied by an altered kinetics of circulating maternal gal-3
levels during gestation. We also found that placental gal-3
expression is downregulated in human pregnancies
complicated with FGR, demonstrating that gal-3 also
plays a role in human FGR pathology. Finally, using
reciprocal matings, we showed that gal-3 within the
maternal compartment is required for proper placental
development and fetal growth. Our findings identify gal-3
as a key component of the molecular program of decid-
ual/placental development and offspring health, as well as
a potential target for future strategies aimed at minimiz-
ing adverse outcomes in pregnancies at high risk for FGR.
Results
Gal-3 deficiency in pregnant mice leads to FGR
To evaluate the contribution of gal-3 during gestation,
we analysed pregnancy outcome and fetal growth in gal-3
deficient mice. Although gestational length was similar
between gal-3 wild type (Lgals3+/+) and deficient
(Lgals3−/−) dams, gal-3 deficient dams displayed an
increased frequency of fetal demise when compared to
their wild type counterparts (Fig. 1a), which is in agree-
ment with observations from other group11. Fetuses car-
ried by Lgals3−/− dams showed a weight reduction of
20–40%, compared with Lgals3+/+ fetuses during
Fig. 1 Gal-3 deficiency leads to FGR. a Macroscopic appearance of the implantation sites on embryonic day (E)13. The pictures show the normal
phenotype of Lgals3+/+ (WT) compared to Lgals3−/− (KO) dams, which exhibit resorbed fetuses (left panel, bar= 1 cm). Abortion rate (%) was
calculated on E13 as follows: abortion rate= (fetal resorptions x 100)/total number of implantations (right panel, n= 19–24). b Fetal body weight (in
grams) of E13 and E17 fetuses carried by Lgals3+/+ (WT) or Lgals3−/− (KO) dams (left panel, n= 13–21). Theiler stage developmental analysis on E13,
upper arrows show that pinna is not turned forward and lower arrows show absence of separated fingers in KO fetuses (bar= 0.25 cm). On E17,
upper arrows display fewer skin wrinkles, smaller whiskers, and lower arrows show that eyes are clearly visible through the eyelids in gal-3 KO fetuses
(bar= 0.5 cm) (right panel). c Mean body weights of pups from Lgals3+/+ and Lgals3−/− dams. Reduced neonatal body weight was observed in
Lgals3 KO offspring, which persisted until postnatal day (P)14 (n= 55–161). d E17 asymmetrical FGR as identified by fetal brain-to-liver weight ratio (n
= 15–30). e Placental weight (mg) observed on E13 and E17 (left panel, n= 13–21). H&E histological analysis of E10 and E13 implantation sites shows
an enlarged decidua in Lgals3−/− mice (middle panel, bar= 500 μm). Isolectin B4 (IB4) analysis of placental depth related to the decidua was
significantly lower in placentas of Lgals3 KO mice (right panel, n= 7–8). f Accumulation of mature NK cells (PAS+DBA+) were significantly elevated at
E13 (left panel, bar= 500 μm, n= 15) and their perforin granules (arrows) were released in gal-3 deficient pregnancy (right panel, bar= 50 μm, n=
8–11). g Progesterone levels measured in E13 serum by ELISA (n= 5). h Quantitative PCR (qPCR) analysis of decidual IFN-Ƴ, TNF-α, TGF-β, IL-10, and IL-
17 gene expression in Lgals3+/+ (WT) and Lgals3−/− (KO) dams at E7 (n= 4–9). In all figures, data are expressed as mean ± SEM. *P < 0.05, †P < 0.01,
and ‡P < 0.001 using two-tailed t test.
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pregnancy, assesed on embryonic day (E)13 and E17 (Fig.
1b). The reduced fetal weight was accompanied by a delay
in fetal development, as the majority of Lgals3−/− fetuses
only reached the Theiler stage (TS)21 on E13, whereas
Lgals3+/+ offspring reached the TS22, which is appro-
priate for the gestational age. The immaturity of gal-3
deficient fetuses was still present on E17, evident as fewer
skin wrinkles, smaller whiskers, and eyes visible through
the eyelids corresponding to TS25 (Fig. 1b). In addition,
we confirmed that Lgals3−/− fetuses suffered from
asymmetric FGR, as denoted by an increased brain-to-
liver weight ratio (Fig. 1d). The reduction of fetal weight
carried over into the postnatal period, as Lgals3−/− off-
spring also showed a significantly reduced body weight
until P14 (Fig. 1c). Upon weaning at 3 weeks of age, both
Lgals3−/− and Lgals3+/+ offspring displayed similar body
weights (Fig. 1c).
Lack of gal-3 during murine gestation is linked to features
of placental insufficiency
Since asymmetric fetal growth primarily arises from
placental pathologies17, we next investigated whether the
lack of gal-3 causes placental insufficiency. We observed
reduced placental weight on E13 and E17 in Lgals3−/−
mice (Fig. 1e). Furthermore, in contrast to wild type dams,
the placental disc in E10 and E13 Lgals3−/− placentas
displayed reduced trophoblast layers with a correspond-
ingly enlarged maternal decidua (Fig. 1e). Improper pla-
cental development in Lgals3−/− mice was accompanied
by a significantly increased abundance of uterine NK
(uNK) cells in the decidua. Here a higher frequency of
uNK cells contained cell-free, perforin-reactive granules
(Fig. 1f). As shown in Fig. 1g, gal-3 deficiency was asso-
ciated with a significant reduction in P4 levels. In line with
this finding, mRNA expression of inflammatory cytokines
(e.g. INF-γ, TNF-α, and IL-17) was significantly increased
in Lgals3−/− decidual tissue (Fig. 1h).
Placental gal-3 deficiency may also affect trophoblast
differentiation during placentation. To address this pos-
sibility, we examined the expression of trophoblast cell
markers between E10 and E13. Our analysis revealed
altered expression of the trophoblast Junb, Gab1, and
Gcm1 genes, a phenomenon that likely contributed to the
failure of placental labyrinth differentiation in Lgals3−/−
placentas (Fig. 2a). To further examine the placental
labyrinth structure, we performed morphological and
functional magnetic resonance imaging (MRI) during E13.
As illustrated in Fig. 2b, placental volume was reduced in
Lgals3−/− compared to Lgals3+/+ implantations. After
injection of an albumin-bound contrast agent, initial
contrast enhancement was significantly higher for
Lgals3−/− mice but contrast material dynamics described
by rate of enhancement were similar (Fig. 2c). Interest-
ingly, the variability of both parameters was much higher
in Lgals3−/− animals. Finally, we used Isolectin
B4 staining to further characterize the Lgals3−/− placental
labyrinth zone. As expected, gal-3 deficiency resulted in
reduced placental labyrinth total vessel length and vessel
area (Fig. 2d).
Reduced maternal levels of gal-3 are linked to human FGR
We next sought to asses the translational relevance of
our findings in mice and determined gal-3 levels in
human pregnancies using biological samples from two
independent patient cohorts. In a subgroup of women
participating in the prospective pregnancy cohort
PRINCE carried out in Germany (clinical data shown in
Supplementary information), we observed that serum
gal-3 levels continuosly increased in normally progres-
sing pregnancies (n= 33) (range 3.02–16.70 ng/ml, Fig.
3a). Conversely, in pregnant women affected by FGR (n
= 32), levels of serum gal-3 were significantly lower as
early as the first trimester and levels stalled throughout
gestation (range 1.00–9.79 ng/ml). In order to asses the
interaction between serum gal-3 levels in human preg-
nancies and placental function, we analysed its correla-
tion with uterine artery perfusion (Ut PI). As suspected,
gal-3 peripheral levels were found to correlate inversely
with Ut PI values (rs=−0.5065, P < 0.05) in pregnancies
complicated with FGR. In addition, we used placental
biopsies taken at birth from uneventful (n= 27) and FGR
pregnancies with placental pathology (n= 19) in an
independent cohort recruited in Australia (clinical data
shown in Supplementary information,18). Similar to our
observations in mice, FGR placentas expressed decreased
protein levels of gal-3 in general as revealed by western
blot (Fig. 3b), or when specifically assessed within the
extravillous CK7+ trophoblasts (Fig. 3c, Supplementary
Fig. 1).
Since placental insufficiency is not exclusive to FGR, we
wondered whether gal-3 dysregulation also occurs in
pregnancies complicated by preeclampsia. Placental
expression and circulating levels of gal-3 in preeclamptic
women (n= 36) from the Oslo study were not different
from those of uneventful pregnancies (n= 23) (Supple-
mentary Fig. 2a–d; clinical data shown in Supplementary
information). Supporting this, gal-3 deficient mice did not
develop preeclampsia-like features (increased blood
pressure, new-onset proteinuria, production of Angio-
tensin II receptor type 1 autoantibody (AT1AA) or cir-
culating anti-angiogenic factors (Supplementary Fig.
2e–h). In addition, no differences were found in E10 and
E13 decidual spiral artery wall thickness between WT and
KO dams (Supplementary Fig. 2i). We conclude that gal-3
deficiency is involved in the placental-fetal axis and con-
fined to the fetal phenotype downstream of placental
pathology without significantly affecting maternal vas-
cular health in pregnancy.
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Maternally-derived gal-3 drives proper placental function
and fetal growth
We next investigated whether maternal gal-3 plays a
role in placental and fetal development. As shown in Fig.
3d, absence of maternal gal-3 increased fetal demise. Most
notably, we observed that the body weight of Lgals3+/−
fetuses derived from Lgals3−/− dams (maternal KO,
mKO) was significantly reduced compared to Lgals3+/−
fetuses carried by Lgals3+/+ dams (paternal KO, pKO).
Also, an immature Theiler stage (TS21), characterized by
a backwards pinna and unseparated fingers (Fig. 3e), was
detected in fetuses derived from Lgals3−/− dams. In
addition, Lgals3+/− implantations carried by Lgals3−/−
dams displayed a decreased fetal/placental weight ratio,
indicative of placental insufficiency (Fig. 3f), along with a
reduction of PAS+ glycogen cells in the junctional zone
(Fig. 3g, Supplementary Fig. 3a). We also identified an
increased uNK cell abundance in the decidua of Lgals3−/−
dams, compared to the reciprocal matings (Fig. 3g, Sup-
plementary Fig. 3b). These findings highlight that
Fig. 2 Gal-3 deficiency results in placenta insufficiency. a Relative mRNA expression of trophoblast differentiation genes determined by
quantitative PCR (qPCR) on E10 and E13 placentas (n= 6–8). b 2D pre-contrast anatomical overview of MR images through abdomen of
representative Lgals3+/+ (WT) and Lgals3−/− (KO) dams. Placentae labeled with false color transparent overlay (top left panel). 3D post-contrast
maximum intensity projection angiograms of the mouse abdomen to determine placental volumes based on contrast enhancement (top right
panel). 3D reconstruction of individual placentas ordered by volume (largest to smallest from left to right) are shown pair wise for Lgals3+/+ (WT) and
Lgals3−/− (KO) animals. For better visual comparison, placental volumes were projected onto discs shown above each reconstruction illustrating
smaller placentas in the Lgals3−/− animals (bottom panel, bar= 8 mm). c Group comparison of placental volumes over all animals confirmed a
decrease in Lgals3−/− animals (top panel). Series of post-contrast images were acquired and mean signal was quantified repetitively for each placenta
over ~10min for functional MRI phenotyping. Initial enhancement, representative of maternal fractional blood volume in percent was increased in
Lgals3−/− placentae whereas the rate of enhancement representative of several functional parameters such as perfusion, contrast agent inflow,
clearance, and uptake was unchanged. Notably, a higher variability was found in KO animals for both, initial (middle panel) and rate (bottom panel) of
enhancement (n= 8–16). d Isolectin B4 (IB4) staining showed poor development of fetal capillaries in the labyrinth of placentae of Lgals3−/− KO mice
as revealed by AngioTool analysis (Total vessel length and vessel area; left bar= 500 μm and right= 150 μm, n= 25–34). In all figures, data are
expressed as mean ± SEM. *P < 0.05, †P < 0.01, and ‡P < 0.001 using two-tailed t test.
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maternally-derived gal-3 maintains placental function. If
maternal gal-3 expression is low, the incidence of devel-
oping FGR is increased.
Discussion
FGR remains one of the “great obstetrical syndromes”,
and is a leading contributor worldwide to perinatal mor-
tality and morbidity, as well as playing an important role
in mediating non-communicable diseases in adult life,
including cardiovascular disease, diabetes, metabolic
syndrome, and obesity. Although significant advances
have been made on its understanding, there is still no
definitive cure or treatment for pregnancies complicated
by FGR. Thus, the current knowledge gap emphasizes the
need for a better understanding of how fetal development
is normally achieved and how it is dysregulated in FGR.
Since normal placental development and functional
integrity are essential for normal fetal growth, the iden-
tification of alterations during critical windows of pla-
cental development could help to optimize antepartum
monitoring and timely delivery of FGR infants. Our study
unveils that a dysregulation of gal-3, especially at the
maternal compartment, is a significant factor involved in
abnormal placentation and development of FGR. This
phenotype appears to be mirrored in human FGR
patients, suggesting that gal-3 can assert similar effects in
the human placenta.
Galectin-3 was initially reported to be a factor related to
endometrial receptivity due to its increased expression in
the endometrium and trophoblast during embryo
Fig. 3 Maternal gal-3 is necessary for normal placental and fetal development. a Circulating maternal gal-3 evaluated by ELISA in PRINCE
cohort of patients (n= 65) during first, second, and third trimester, where some women subsequently development FGR (n= 32). b Western blot
analysis of gal-3 expression in placental tissue from normal, healthy human pregnancies (NP) (n= 27) and pregnancies complicated by FGR (n= 19).
Densitometry was performed to quantify changes in protein expression using ImageJ. c Representative images of gal-3 and cytokeratin (CK) 7
immunohistochemistry in NP and FGR placentae (n= 14, bar= 100 μm; left panel). The percent staining area of gal-3 and CK7 slides was quantified,
and a ratio was calculated by dividing the percent area of gal-3 to CK7 staining in slides from the same placental tissue sample (right panel). d
Schematic diagram showing the lack of paternal (mating of Lgals3−/− (KO) male with Lgals3+/+ (WT) female, pKO) and maternal (mating of Lgals3+/+
(WT) male with Lgals3−/− (KO) female, mKO) gal-3. The offspring is heterogeneous (HT) for gal-3 in both mating combinations (left panel). The
abortion rate was calculated on E13 as follows: abortion rate= (fetal resorptions x 100)/total number of implantations (middle panel, n= 6–8).
Pictures display whole implantation sites on E13. Arrows point to fetal resorptions (right panel, bar= 1 cm). e The embryo body weight was
determined on E13 to identify potential fetal growth restriction (FGR) (n= 6). To assess the fetal development, Theiler stage (TS) analysis was
performed. Normally developed embryos on E13 are in TS22 (pKO). FGR embryos are in a lower stage (e.g., TS21 or 21.5) and are characterized by a
pinna that is not turned forward and non-separated fingers (arrows; mKO) (bar= 0.25 cm). f Placental efficiency was calculated as fetal/placental
weight ratio on E13 (n= 14–21). g Glycogen cells in the spongiotrophoblast of the placenta were stained with periodic acid Schiff (PAS) and counted
in 3 squares (1 × 1 mm) per mouse on E13 (n= 14–21). The number of mature uterine natural killer (uNK) cells in the decidua basalis were counted in
3 to 4 squares (1 × 1 mm) per mouse (n= 19–26). In all figures, data are expressed as mean ± SEM. *P < 0.05, †P < 0.01, and ‡P < 0.001 using two-tailed
t test.
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implantation19,20. Subsequent studies have revealed that
endometrial gal-3 is involved in embryo implantation21
and dysregulation of placental gal-3 is associated with
adverse pregnancy outcomes12–16,22,23. The present study
demonstrates that gal-3 is critical for orchestrating heal-
thy fetal-maternal interface interactions and its dysregu-
lation results in asymmetric FGR. Affecting approximately
70% of growth-restricted fetuses, the asymmetric type of
FGR occurs when brain growth and maturity is main-
tained while the visceral organs (especially the liver) have
relatively reduced weights24, and represents a later timing
of embryonic damage that results from maternal vascular
factors and/ or placental insufficiency. The fact that gal-3
deficiency-induced asymmetric growth restriction fol-
lowed by relatively rapid catch-up growth is of significant
importance since human babies with these characteristics,
particularly those with accelerated postnatal weight gain
after in utero growth restriction, have a greatly enhanced
risk of developing type 2 diabetes, obesity and cardio-
vascular disease25–27.
Studies in gal-3 deficient dams enabled us to identify
this chimera lectin as a key player in regulating decid-
ualization and maternal immune adaptation during early
gestation. The absence of gal-3 per se induced decidual
enlargement, inflammatory cytokine gene expression, and
NK cell infiltration with aberrant activation. Supporting
our observations, these features were also found in a
different mouse FGR model established by independent
researchers28. Gal-3 is known to regulate immune
responses, acting as a pro-inflammatory signal with
diverse innate immune cell targets to promote their
activation, degranulation, and cytokine production29,30. In
this context, recent in vitro studies have shown that
endogenous expression of gal-3 in human NK cells can be
stimulated by activating cytokines (IL-2, IL-15) and cor-
relates functionally with their degree of cytotoxic degra-
nulation31. While similar functions remain to be
examined in the context of pregnancy, the identification
of an endogenous gal-3 ligand localizing specifically to
mouse uNK perforin granules32 implies a potential role of
this lectin in controlling the activation status of this
particular lymphocyte subset, which has been ascribed
important roles in the modulation of decidual develop-
ment, trophoblast invasion, and maternal vascular remo-
deling during early pregnancy.
Gal-3 deficiency impacts placental function by means of
intrinsic effects on trophoblast biology. Specifically, we
showed that gal-3 deficiency during gestation alters tro-
phoblast differentiation, vascularization of the labyrinth
zone and subsequently causes changes in placental per-
fusion. While the structural organization of the fetal-
maternal interface differs between human and mouse
(villous versus labyrinthine placenta), the syncytium
separates fetal and maternal blood in both species and
serves analogous functions. Therefore, it is not surprising
that gal-3 deficiency compromised the labyrinth layer
during mouse placentation. Since inflow and clearance of
the contrast agent strongly depend on perfusion, we
speculate on more heterogeneous maternal circulation in
gal-3 deficient compared to control placentas. Indeed, gal-
3 deficiency caused reduced total vessel length and vessel
area in the placental labyrinth, suggesting that absence of
this lectin during gestation alters vascularization of the
labyrinth and subsequently results in placental mal-
perfusion. On the other hand, maternal deficiency of gal-3
also provoked alterations in placental structure, particu-
larly in glycogen cells of the junctional zone, emphasizing
the importance of an interplay between fetal and maternal
sources of gal-3 expression for normal placental devel-
opment. Alterations in placental energy storage (glycogen
cells) are a typical feature of FGR models and likely to
contribute to the detrimental maternal effect on fetal
growth33,34. A reduced placental glycogen reserve will
definitely impact on placental well-being and fetal growth
as the main source of energy for the placenta comes from
glucose and also, the glycogen stores may be destined to
the fetal demands35. In addition, glycogen trophoblasts
may serve other functions likely to impact fetal growth, as
these cells invade the decidua congregating near spiral
arteries to support their remodeling and also have an
endocrine role, being the source of several mediators
including retinoic acid, prolactin-like hormones and
particularly IGF-2, a crucial modulator of placental and
fetal growth33,36.
Finally, our results showing dysregulated gal-3 expres-
sion in human pregnancies affected by impaired fetal
growth are consistent with the role played by this lectin in
pregnancy orchestration as demonstrated in our mouse
studies. Particularly, the fact that besides sharing a com-
mon placental histopathology, FGR and PE placentas
differed in their pattern of regulation of gal-3 expression
is of great importance. Our clinical and experimental
findings demonstrated that gal-3 loss of function is not
sufficient to provoke a maternal PE-like syndrome in
mice, and women with both early and late-onset PE
showed no alterations in gal-3 expression. Because gal-1
and gal-3 are the most prominent galectins associated
with critical processes in early gestation, we hypothesize
that unique properties exerted by gal-3 in supporting
placental development, fetal growth, and pregnancy can-
not be substituted by gal-1. Our study is clinically relevant
as it provides important insights into the role of gal-3
during gestation, highlighting its requirement for proper
placental development and function and fetal growth. It
also reinforces the concept that unique functional prop-
erties in support of healthy pregnancy are specific to each
of the different members of the placental galectin
network.
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Materials and methods
Mice
C57BL/6 Lgals3+/+ and Lgals3−/− mice were purchased
from Jackson Laboratories. The presence of a vaginal plug
after mating was denoted as embryonic day (E) 0. Timed
pregnant Lgals3+/+ and Lgals3−/− mice were evaluated at
E7, E10, E13, E17, P4, and P21 (n= 7–9 mice per group)
and approved by Charité and Berlin authority for Animal
Use in Research and Education. A second experiment
used Lgals3+/+or Lgals3−/− females mated with Lgals3−/−
or Lgals3+/+ males respectively to create the “paternal”
(pKO) or “maternal” (mKO) gal–3 deficiency. On E13,
after euthanizing the mice, the percentage of failed
implantations was calculated (non-viable implantations/
total implantation ×100) and whole implantation sites
were frozen for histological sectioning and isolation of
total protein or total RNA according to our published
procedures7. Embryos were fixed in Bouin’s solution and
subsequently cleared in 70% v/v ethanol for body weight
measurement and Theiler stage analysis37. Placenta effi-
ciency was calculated as “fetal/placental weight ratio” and
used to measure nutrient transfer capacity from the pla-
centa to the fetus.
Human samples
Three patient cohorts were used in this study. The
prospective human low-Risk pregnancy cohort PRINCE
(Prenatal Identification of Children’s Health, Ethics
Committee: PV3694) is based at the university medical
center in Hamburg, Germany. Since 2012 a total number
of 721 women have been included during early pregnancy
and examined a total of three times during the course of
the pregnancy (14th, 24th, and 36th week of pregnancy).
In addition to collecting demographic details and psy-
chosocial factors, these prenatal study visits involved
extensive ultrasound examinations of fetal growth and
placental function, nutritional behavior, medication
intake, and vaccinations during pregnancy. Blood was
drawn at each of the three-time points.
For analyses of gal–3 expression in pregnancy affected
only by FGR, patient samples from the research bio-bank
collection at the Kolling Institute, Sydney, Australia were
used. Use was approved by the Northern Sydney Local
Health District Human research Ethics Committee, (St
Leonards, NSW, Australia) and was assigned the site-
specific assessment number 0912-348M and the Aus-
tralian national ethics application form number HREC/
09/HARBR/165 as described18.
For analyses of gal–3 expression in pregnancy affected
by preeclampsia, patient samples from the Oslo Preg-
nancy Biobank research collection at Oslo University
Hospital, Oslo, approved by the Regional Committee of
Medical Research Ethics in Eastern Norway, were used as
described38. Circulating soluble fms-like tyrosine kinase-1
(sFlt-1) and placenta growth factor (PlGF) levels were
determined by commercial ELISA from R&D Systems
following the manufacturer’s recommendations. The
clinical characteristics of the human cohorts are sum-
marized in Supplementary information.
Histological analysis
Serial paraffin-embedded uterine sections from Lgals3+/
+ and Lgals3−/− mice at E13 were cut into 4 μm-thick
sections and stained with hematoxylin-eosin (H&E), PAS,
Masson-Goldner’s trichrome, Dolichos biflorus agglutinin
(DBA) lectin/PAS and Isolectin B4 as previously descri-
bed39. Whole implantation sites were stained and digitally
scanned by a high-resolution bright field and fluorescence
slide scanner (Pannoramic MIDI BF/FL, 3DHISTECH
Ltd.), and staining was evaluated on virtual slides using
Pannoramic Viewer 1.15.4 (3DHISTECH Ltd.) by two
examiners blinded to the pregnancy outcome.
Magnetic resonance imaging
MRI measurements for in vivo phenotype of Lgals-3-
deficient mice at E13 were performed in a dedicated 7 T
small animal scanner (Biospec, Bruker BioSpin, Ettlingen,
Germany). The imaging protocol was adapted from a
previous study by Plaks and coworkers40. Full details on
the MRI protocol is provided in the Supplementary
information.
Galectin-3 ELISA
Gal-3 concentrations in the serum of pregnant patients
were determined by ELISA as described previously41.
Briefly, immunolon 2 ELISA plates (Dynatech Labora-
tories, USA) were covered with polyclonal antihuman gal-
3 antibody (1 μg/ml; AF1154, R&D Systems, USA) and
washed with washing buffer (0.5% Tween-20 in PBS).
Plates were blocked with 3% BSA in PBS. Individual wells
were incubated with serial dilutions of gal-3 (1154-GA,
R&D Systems, USA) or serum samples (diluted 1/10) for
2 h at RT. Wells were washed and incubated with bioti-
nylated polyclonal antihuman gal-3 antibody (0.25 μg/ml
in PBS 0.1% BSA; BAF1154, R&D Systems, USA). Plates
were washed six times and incubated with horseradish
peroxidase (HRP)-conjugated streptavidin (Calbiochem,
USA). After eight additional washes, a colorimetric reac-
tion was developed with the 3,3,5,5′-tetramethyl benzidine
(TMB) substrate (Pierce Biotechnology, USA). The reac-
tion was stopped by adding one volume of 4 N H2SO4.
Absorbance at 450 nm was recorded. Each reported value
is the mean of triplicate assays.
Gal-3 western blotting
Protein was extracted from frozen placental tissue and
10 µg of protein lysate was separated by SDS-PAGE as
described previously19. Immunoblotting was performed
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for gal-3 (1:1000, Santa Cruz Biotechnology SC-20157) or
β-actin (loading control) and protein expression was
detected using the appropriate HRP-conjugated second-
ary antibodies (1:3000, Bio-Rad).
Galectin-3 staining in human samples
Immunohistochemistry was performed on formalin-
fixed, paraffin-embedded placental tissues from both
normal and FGR pregnancies as previously described19.
Slides were incubated with gal-3 (0.5 µg/ml; Santa Cruz
Biotechnology sc-32790), cytokeratin 7 (0.09 µg/ml;
Abcam ab68459) or isotype controls at equivalent con-
centrations, visualized using NovaRed peroxidase HRP
substrate kit (Vector Laboratories) and staining quanti-
tated using ImageJ.
Statistical analysis
Data are expressed as mean ± SEM. Mouse and human
data were analysed using the non-parametric
Mann–Whitney U-test. GraphPad Prism 8.0 (GraphPad
Software, Inc.) was used to analyse the data and a P value
<0.05 was considered as statistically significant.
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